Why the study?
Despite numerous international guidelines for Kawasaki disease, there has been no comparison of them, and optimal treatment for high-risk and refractory disease lacks evidence.
This review highlights the consensus on first-line IVIG and aspirin for Kawasaki disease across international guidelines, while identifying discrepancies in aspirin dosing and the management of IVIG-resistant and high-risk patients.
Answers are grounded in this paper and cite their sources.
Guideline comparison in KD reveals consistent IVIG-aspirin core but divergent adjunct recommendations; leaves open evidence-based optimization.
Kawasaki disease (KD), an acute, generalized vasculitis, is associated with an increased risk of coronary heart disease and is the most common cause of acquired heart disease in childhood. The incidence of KD is increasing worldwide. There are numerous international treatment guidelines. Our study aims to perform the first one so far comparison of them. While the gold standard therapy remains still the same (intravenous immunoglobulins and aspirin), there is currently a lack of evidence for choosing optimal treatment for high-risk patients and refractory KD. In this review, we also discuss the treatment of complications of KD and Kawasaki-like phenotypes, present an anti-inflammatory treatment in the light of new scientific data, and present novel potential therapeutic targets for KD.
No takes yet. Share an insight, caveat, or question.
Buda et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: